The conclusions from previous molecular docking studies suggest PTP1B, α-glucosidase, DPP-IV, and PPAR-γ as plausible targets that explain the hypoglycemia activity of MB extract [42,43,44]. The gene discussed is PTPN1; the disease is Hypoglycemia.